anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To summarize the distribution of types of human papillomavirus (HPV) associated with HPV-related diseases and investigate the potential causes of high prevalence of HPV 52 and 58 by summarizing the prevalence of lineages, sub-lineages, and mutations among Chinese women. We searched PubMed, EMBASE, CNKI, and WanFang from January, 2012 to June, 2023 to identify all the eligible studies. We excluded patients who had received HPV vaccinations. Data were summarized in tables and cloud/rain maps. A total of 102 studies reporting HPV distribution and 15 studies reporting HPV52/HPV58 variants were extracted. Among Chinese women, the top five prevalent HPV types associated with cervical cancer (CC) were HPV16, 18, 58, 52, and 33. In patients with vaginal cancers and precancerous lesions, the most common HPV types were 16 and 52 followed by 58. For women with condyloma acuminatum (CA), the most common HPV types were 11 and 6. In Chinese women with HPV infection, lineage B was the most prominently identified for HPV52, and lineage A was the most common for HPV58. In addition to HPV types 16, which is prevalent worldwide, our findings revealed the unique high prevalence of HPV 52/58 among Chinese women with HPV-related diseases. HPV 52 variants were predominantly biased toward lineage B and sub-lineage B2, and HPV 58 variants were strongly biased toward lineage A and sub-lineage A1. Further investigations on the association between the high prevalent lineage and sub-lineage in HPV 52/58 and the risk of cancer risk are needed. Our findings underscore the importance of vaccination with the nine-valent HPV vaccine in China.
The invention relates to an Enteromorpha prolifera toothpaste. The Enteromorpha prolifera toothpaste is characterized in that the toothpaste is produced by using pure natural Enteromorpha prolifera, glycerol, calcium hydrogen phosphate dihydrate, sodium lauroyl sarcosinate, peppermint oil, saccharin, deionized water, sodium carboxy methyl cellulose and sodium pyrophosphate through glue preparation, mixing, grinding, degassing, aging and filling. The tooth paste has the effects of tooth cleaning, inflammation eliminating, pain relieving, allergy preventing, oral ulcer preventing and treating, and deodorizing. Enteromorpha prolifera is rich in polysaccharides, and has antitumor, antiviral and antibacterial effects. Marine oligosaccharides can be extracted from Enteromorpha prolifera, and have carious tooth preventing and human body immunity enhancing functions. Enteromorpha prolifera is also rich in chlorophyll, and has special gum bleeding stopping and bad breath preventing effects. The toothpaste produced by using Enteromorpha prolifera keeps the original tooth cleaning function of a toothpaste, and also has the efficacies of inflammation eliminating, pain relieving, oral ulcer and gum bleeding preventing and treating, and bad breath preventing. The Enteromorpha prolifera toothpaste is a multifunctional medicinal toothpaste, and is suitable for all people to use.
The present invention relates to a composition for promoting bacterial proliferation for selectively proliferating  Lactobacillus casei  subsp.  casei , which includes a dextran. According to the present invention, a variety of biological activities originated from  L. casei  subsp.  casei  can be sustained in a living body by selectively growing-proliferating and colonizing  L. casei  subsp.  casei  in the intestine of a human being, animal, or the like or by selectively growing-proliferating  L. casei  subsp.  casei  in the intestine, without supplying  L. casei  subsp.  casei  at all times.
Leprosy is a neglected contagious disease that causes physical disability and episodes of inflammation, called leprosy reactions. There are currently no consolidated laboratory markers that can predict or confirm the diagnosis of leprosy reactions, negatively impacting the progression of the disease. The aim of this study was to analyze the behavior of inflammatory biomarkers in a population of patients with multibacillary leprosy. This prospective study in a northeastern capital involved 67 new cases of multibacillary leprosy, assessing inflammatory biomarkers at diagnosis. Histopathology, qPCR, slit skin smear microscopy, and laboratory tests, including CRP-albumin, neutrophil-lymphocyte, lymphocyte-monocyte, platelet-lymphocyte ratios, and systemic immune-inflammation index, were conducted. Statistical analysis utilized Stata version 16.0®, employing Chi-square, Kruskal-Wallis, and Poisson regression (5% significance). The population, mainly young brown men with low socioeconomic status, borderline leprosy, and and degree of physical disability one, saw 19.4% experiencing leprosy reactions. Standard multibacillary multidrug therapy was administered to all. Ratios and index values exceeding medians were prevalent (46.3-47.8%). Assessing biological markers against leprosy reactions revealed a positive relation between reactions and lymphocyte-platelet ratio (p = 0.05) and a positive trend with the systemic immune-inflammation index (p = 0.06). Patients with reactions were 1.3 times more likely to exhibit an elevated lymphocyte-platelet ratio. The lymphocyte-platelet ratio emerged as a potential indicator for recognizing leprosy reactions. Further research is essential to validate these findings, aiming for earlier detection of leprosy reactions.
The invention discloses a hybridoma cell strain, the preservation number of which is CGMCC No. 18521. The invention also discloses a monoclonal antibody secreted and produced by the hybridoma cell strain CGMCC No. 18521. The invention also discloses a coding gene of the monoclonal antibody, recombinant anti-porcine APN protein antibody protein expressed in vitro and a preparation method thereof, and application of the antibody protein in preparing a medicament or vaccine for preventing or treating intestinal diseases. The APN antibody obtained by the invention can be specifically combined with porcine APN protein, has strong affinity and good stability, and lays a foundation for further researching the function of APN and developing genetic engineering antibody medicines and novel vaccines.
Treatment with opioids can improve activity related dyspnea by reducing central respiratory neural drive. Inhaled fentanyl citrate is an opioid that is generally well tolerated and has been shown to effectively relieve respiratory discomfort without causing systemic side-effects, although its mechanism of action are poorly understood. Based on the current evidence, non-sedating, rapidly active inhaled fentanyl represents a possible alternative and effective treatment of severe dyspnea in patients with ILD who require urgent treatment. As such, the primary objective of this study is to examine the acute effects of nebulized fentanyl on dyspnea intensity and quality in patients with mild-to-moderate ILD, as well as examine the neurophysiological mechanisms of dyspnea relief during fentanyl inhalation. It is believed that fentanyl when compared with placebo, will reduce inspiratory neural drive to the diaphragm and breathing frequency, resulting in improvements in dyspnea intensity during physical exertion. Alternatively, dyspnea relief after inhaled fentanyl may be independent of changes in neural drive, and instead linked to the presence of opioid receptors in the lungs that modulate afferent inputs to the brain, thereby favourably influencing perceived dyspnea.
Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. The aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.
The invention belongs to the field of animal pharmaceutical preparations, and relates to houttuynia cordata injectable in situ gel as well as a preparation method thereof. The in situ gel comprises the following components in parts by weight: 40.0-75.0 parts of fresh Houttuynia cordata distillate, 16.5-29.5 parts of poloxamer 407 (P407), 0.5-11.5 parts of poloxamer 188 (P188), 0.02-11.0 parts of a high molecular retardant, 0.1-10.0 parts of a solubilizing stabilizer and 0.01-3.0 parts of a preservative. The obtained preparation per milliliter is equivalent to 6.0-10.0g of a fresh product of a crude drug. The preparation provided by the invention is a liquid freely flowing at room temperature, forms a semisolid gel after being given by intramuscular injection or subcutaneous injection, and can continuously and stably release drugs, so that the in situ gel is just given once in a course of treatment. The in situ gel has the advantages of simple preparation, stable property, convenient administration, definite curative effect, strong animal adaptability and the like. The preparation provided by the invention has wide pharmacological effects such as antibacterial effect, antivirus effect, anti-inflammatory effect and immunoregulation, and is applicable to preventing and treating diseases of animals such as pigs, cattle, sheep, dogs and cats.
Disclosed are an IoT system and a monitoring method for monitoring association between indoor environment and health of elderly people. Such IoT system comprises an environmental and health parameter monitoring system and an IoT data association platform, the monitoring system performs data transmission with the IoT data association platform by a GPRS wireless communication module and a data receiving API interface. The monitoring system is combined with the IoT data association platform. The IoT system has a small physical volume and can be fixed to the periphery of the human body by wearing. The constructed IoT environment and health association data platform can remotely and online monitor change of the temperature and humidity and particle concentration in the environment where elderly people are located, and remotely and online monitor the blood pressure and heart rate of elderly people. The health risks can be predicted in real time by input environmental data.
BACKGROUND: Sudden death accounts for approximately 10% of deaths among working-age adults and is associated with poor air quality. Objectives: To identify high-risk groups and potential modifiers and mediators of risk, we explored previously established associations between fine particulate matter (PM2.5) and sudden death stratified by potential risk factors.
METHODS: Sudden death victims in Wake County, NC, from 1 March 2013 to 28 February 2015 were identified by screening Emergency Medical Systems reports and adjudicated (n = 399). Daily PM2.5 concentrations for Wake County from the Air Quality Data Mart were linked to event and control periods. Potential modifiers included greenspace metrics, clinical conditions, left ventricular hypertrophy (LVH), and neutrophil-to-lymphocyte ratio (NLR). Using a case-crossover design, conditional logistic regression estimated the OR (95%CI) for sudden death for a 5 μg/m3 increase in PM2.5 with a 1-day lag, adjusted for temperature and humidity, across risk factor strata.
RESULTS: Individuals having LVH or an NLR above 2.5 had PM2.5 associations of greater magnitude than those without [with LVH OR: 1.90 (1.04, 3.50); NLR > 2.5: 1.25 (0.89, 1.76)]. PM2.5 was generally less impactful for individuals living in areas with higher levels of greenspace.
CONCLUSION: LVH and inflammation may be the final step in the causal pathway whereby poor air quality and traditional risk factors trigger arrhythmia or myocardial ischemia and sudden death. The combination of statistical evidence with clinical knowledge can inform medical providers of underlying risks for their patients generally, while our findings here may help guide interventions to mitigate the incidence of sudden death.
BACKGROUND: The hospital wastewater system has been reported as a source of nosocomial acquisition of carbapenemase producing Enterobacteriaceae (CPE) in various settings. Cleaning and disinfection protocols or replacement of contaminated equipment often fail to eradicate these environmental reservoirs, which can lead to long-term transmission of CPE. We report a successful multimodal approach to control a New Delhi metallo-beta-lactamase positive Klebsiella pneumoniae (NDM-KP) nosocomial outbreak implicating contamination of sink traps in a low-incidence setting.
METHODS: Following the incidental identification of NDM-KP in a urine culture of an inpatient, we performed an epidemiological investigation, including patient and environmental CPE screening, and whole genome sequencing (WGS) of strains. We also implemented multimodal infection prevention and control (IPC) measures, namely the isolation of cases, waterless patient care, replacement of contaminated P-traps and connecting pieces, and bleach and steam disinfection of sinks for 6 months, followed by patient and environmental screenings for eradication.
RESULTS: Between February and May 2022, five NDM-KP cases were identified in an eight-bed neurosurgical intermediate care unit. Among the eight sink traps of the unit, three were positive for NDM-KP. Patient and environmental isolates belonged to multilocus sequence typing ST-268. All isolate genomes were genetically very similar suggesting cross-transmission and a potential role of the environment as the source of transmissions. Following the introduction of combined IPC measures, no new case was subsequently detected and sink traps remained negative for NDM-KP within 6 months after the intervention.
CONCLUSION: The implementation of multimodal IPC measures, including waterless patient care combined with the replacement and disinfection of P-traps and connecting pieces, was successful in the control of NDM-KP after eight months. In a low-incidence setting, this approach has made it possible to pursue the objective of zero transmission of carbapenemase-producing Enterobacteriaceae (CPE).
The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
FIELD: organic chemistry, heterocyclic compounds, pharmacy. SUBSTANCE: invention relates to a compound of the formula (I)   that shows neuroleptic property. Compound (I) is synthesized by partial reduction of pyridinium salt of compound of the formula (IV)   where W - an organic or an inorganic ion with metal boron hydride in protonic solvent. Synthesized compound is used for treatment of patients with schizophrenia and other psychosis. EFFECT: improved method of synthesis and producing, enhanced efficiency. 9 cl, 5 ex
PURPOSE: A medicinal composition containing mesenchymal stem cells or culture medium thereof for preventing or treating neural disease is provided to suppress neural cell toxicity and tau protein phosphorylation and to induce expression of neprilysin. CONSTITUTION: A medicinal composition for preventing or treating Alzheimer disease contains mesenchymal stem cell or culture medium thereof. The mesenchymal stem cell is umbilical cord blood mesenchymal stem cell or bone marrow-derived stem cell. The culture medium contains activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin1, WISP1, or progranulin. A medicinal composition for preventing or treating diseases caused by damage of neurite contains mesenchymal stem cell or culture medium thereof. The diseases are Alzheimer disease, Parkinson's disease, depression, stroma, multiple sclerosis or mania.
Producing polymerizate comprises polymerizing monomers of a polymer A or B partially or virtually completely, and adding the monomers of respective other polymer, subsequently polymerizing the monomers of respective other polymer and the partially polymerized polymer A or B, or polymerizing the virtually completely polymerized polymer A or B, with the formation of a mixture of polymer A and polymer B. The polymerizate includes mixture of polymer A including e.g. alkyl-methacrylate, methacrylic acid, and polymer B including e.g. a monomer carrying an amide group and optionally other monomers. Producing polymerizate comprises polymerizing monomers of a polymer A or B partially or virtually completely, and adding the monomers of respective other polymer, subsequently polymerizing the monomers of respective other polymer and the partially polymerized polymer A or B, or polymerizing the virtually completely polymerized polymer A or B, with the formation of a mixture of polymer A and polymer B. The polymerizate includes the mixture of at least one polymer A and at least one polymer B, where (A) polymer A comprises (in wt.%): (a1) alkyl-methacrylate having 1-4C (30-70), (a2) methacrylic acid (30-70), (a3) monomers substituted with 8-30C (0 -20), (a4) monomers more different from (a1) to (a3) (0 -20), and (B) polymer B comprises (in wt.%): (b1) at least one monomer carrying at least one amide group, and (b2) optionally other monomers different from the (b1), where the components of the polymers A and B are present in a copolymerized form. and (B) Polymer B comprises in copolymerized form. Independent claims are also included for (1) the polymerizate obtainable by the above method; and (2) treating hair comprising contacting the hair with the above obtained polymerizate.
After a complete response (PLT ≥100x10\^9/L) was confirmed, the dose of prednisone (or equivalent dose of glucocorticoids) would be reduced by 2 tablets every two weeks. When it reaches 6 tablets /d, the dose would be reduced by 1 tablet every 2 weeks, and when it reaches 15mg/d, the dose would be reduced by half tablet every 2 weeks.
BACKGROUND: Due to the presence of other comorbidities and multi-therapeutic modalities in breast cancer, renally cleared chemotherapeutic regimens may cause nephrotoxicity. The aim of this retrospective study is to compare the chemotherapy types and outcomes in breast cancer patients with or without chronic renal disease.
PATIENTS AND METHODS: We retrospectively enrolled 62 female patients with breast cancer and underlying late stages (stage 3b, 4, and 5) of chronic kidney disease (CKD) treated from 2000 to 2017. They were propensity score-matched 1:1 with patients in our database with breast cancer and normal renal function (total n = 124).
RESULTS: The main subtype of breast cancer was luminal A and relatively few patients with renal impairment received chemotherapy and anti-Her-2 treatment. The breast cancer patients with late-stage CKD had a slightly higher recurrent rate, especially at the locally advanced stage. The 5-year overall survival was 90.1 and 71.2% for patients without and with late-stage CKD, but the breast cancer-related mortality rate was 88.9 and 24.1%, respectively. In multivariate analyses, dose-reduced chemotherapy was an independent negative predictor of 5-year recurrence-free survival and late-stage CKD was associated with lower 5-year overall survival rate.
CONCLUSIONS: Breast cancer patients with late-stage CKD may receive insufficient therapeutic modalities. Although the recurrence-free survival rate did not differ significantly by the status of CKD, patients with breast cancer and late-stage CKD had shorter overall survival time but a lower breast cancer-related mortality rate, indicated that the mortality was related to underlying disease.
The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the β-A4 peptide/Aβ4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided. The antibody isoforms may for example be used in the pharmaceutical intervention of amyloidogenesis or amyloid-plaque formation and/or in the diagnosis of the same.
PROBLEM TO BE SOLVED: To maintain the starting and persistent muscular strength at the time of motion by orally ingesting branched chain amino acids. SOLUTION: Branched chain amino acids containing (A) leucine, (B) isoleucine and (C) valine as active ingredients are included so as to preferably provide 1:2:1 formulation ratio of the ingredients A:B:C and orally ingested. When the branched chain amino acids are orally ingested, the daily dose thereof for an adult is about 500-2,000 mg expressed in terms of the active ingredients and ingested in divided one to several portions to thereby provide desired effects without adverse effects. The breakdown of muscles is suppressed by ingesting a branched chain amino acid formulated preparation before motion to improve the deterioration in muscular strength, muscular fatigue, central fatigue, etc. The branched chain amino acids are directly degraded and oxidized in peripheral muscular tissues to provide an energy source.  Since the muscular metabolism is promoted and hydrolysis of myoproteins is suppressed, the consumption of muscles can be prevented to restore the muscles in a short time.